Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease
Status:
Active, not recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effect of iron chelation as a therapeutic strategy to slow the
progression of Parkinson's disease. Half of participants will receive the deferiprone to 15
mg / kg twice daily morning and evening (30mg / kg per day), while the other half will
receive a placebo. The treatment lasts nine months.